A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

Overview of attention for article published in BMC Cancer, October 2015

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 40 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 233 followers.

◈ A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line... http://t.co/KpftgvF7J2 ◈

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.